Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23853338 | 1.00 | NAAA (0.44) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23852631 | 1.00 | NAAA (0.44) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23852516 | 1.00 | NAAA (0.44) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23853118 | 1.00 | NAAA (0.44) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23851907 | 0.98 | NAAA (0.41) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23853241 | 0.93 | ALDH1A1 (0.38) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23853244 | 0.93 | ALDH1A1 (0.38) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23852472 | 0.88 | NAAA (0.39) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23852581 | 0.88 | NAAA (0.39) | NAAACA12CA1CA2CA9 | |
| SCHEMBL23852345 | 0.88 | NAAA (0.39) | NAAACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885334-B1 | PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME | SHINETSU CHEMICAL CO (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-11420919-B2 | Process for preparing a formylalkenyl alkoxymethyl ether compound and processes for preparing conjugated diene compounds from the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20210300854-A1 | PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| EP-3885334-A1 | PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300854-A1 | PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME | ADH1C, ORC3, ADH1A | NAAA 1312/4885CA12 624/4885CA1 464/4885 |
| US-11420919-B2 | Process for preparing a formylalkenyl alkoxymethyl ether compound and processes for preparing conjugated diene compounds from the same | ADH1C, ORC3, ADH1A | NAAA 1312/4885CA12 624/4885CA1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.